Nebulized drug admixtures: Effect on aerosol characteristics and albuterol output

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 4, 2006, Pages 484-490

  Berlinski, Ariel ^a,c   Waldrep, J Clifford ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b University of Missouri   (United States)

^c UAMS COM ^*  (United States)

Author keywords

Albuterol; Cystic fibrosis; Drug admixtures; Nebulizers; Particle size

Indexed keywords

ACETYLCYSTEINE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; IPRATROPIUM BROMIDE; SALBUTAMOL; TOBRAMYCIN SULFATE;

AEROSOL; ARTICLE; BREATH ENHANCED NEBULIZER; CHEMICAL ANALYSIS; CONTINUOUS OUTPUT NEBULIZER; DEVICE; DRUG MIXTURE; INTERMETHOD COMPARISON; KINETICS; MASS MEDIAN AERODYNAMIC DIAMETER; MOLECULAR DYNAMICS; NEBULIZATION; NEBULIZER; PARAMETER; PARTICLE SIZE; STATISTICAL ANALYSIS;

ADRENERGIC BETA-AGONISTS; AEROSOLS; ALBUTEROL; ANTI-BACTERIAL AGENTS; CROMOLYN SODIUM; DRUG COMBINATIONS; EQUIPMENT DESIGN; FLUOCINOLONE ACETONIDE; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; TOBRAMYCIN;

EID: 33846116201     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.484     Document Type: Article

References (33)

1. Boe, J., J.H. Dennis, and J. O'Driscoll. 2000. European respiratory society nebulizer guidelines: clinical aspects. Eur. Respir. Rev. 10:76.
2. Borsje, P., J.C. de Jongste, J.W. Mouton, et al. 2000. Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. Pediatr. Pulmonol. 30:368-376.
3. Barry, P.W. and C. O'Callaghan. 1997. Nebulizer therapy in childhood. Thorax 52:S78-S88.
4. Rosenfeld, M., J. Emerson, S. Ashley, et al. 1998. Home nebulizer use among patients with cystic fibrosis. J. Pediatr. 132:125-131.
5. Pujol, M.S., C. Menat, T. Henon, et al. 2000. Prescriptions of aerosol therapy. A survey of practices at the Besancon University Hospital. Presse Med. 29:824-828.
6. Lesko, L.J. and Miller, A.K. 1984. Pysical-chemical compatibility of cromolyn sodium nebulizer solution-brochodilator inhalant solution admixtures. Ann. Allergy 53:236-238.
7. Iacono, M., G.J. Johnson, and R.W. Bury. 1987. An investigation of the compatibility of ipratropium and sodium cromoglycate nebuliser solutions. Aust. J. Hosp. Pharm. 17:158-161.
8. Roberts, G.W., and S.O.P. Rossi. 1993. Compatibility of nebulizer solutions. Aust. J. Hosp. Pharm. 23:35-37.
9. Emm, T., J.E. Metcalf, L.J. Lesko, et al. 1991. Update on the physical-chemical compatibility of cromolyn sodium nebulizer solution: bronchodilator inhalant admixtures. Ann. Allergy 66:185-189.
10. Joseph, J.C. 1997. Compatibility of nebulizer solution admixtures. Ann. Pharmacother. 31:487-489.
11. McKenzie, J.E., and M. Cruz-Rivera. 2004. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann. Pharmacother. 38:967-972.
12. Gooch, M.D. 1991. Stability of albuterol and tobramycin when mixed for aerosol administration. Respir. Care 36:1387-1390.
13. Coates, A.L., C.F. MacNeish, D. Meisner, et al. 1997. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 111:1206-1212.
14. Di Berdino, L., and F. Scaglione. 1999. Mixing albuterol and corticosteroid is not additive. Allergy 54:1012-1013.
15. Hess, D.R. 2000. Nebulizers: principles and performance. Respir. Care 45:609-622.
16. Berlinski, A., and J.C. Waldrep. 2001. Aerosol characterization of nebulized intranasal glucocorticoid formulations. J. Aerosol. Med. 14:237-246.
17. Allen, E.D., E.R. Whitaker, and G. Ryu. 1997. Six-week trial of nebulized Fluisolide nasal spray: efficacy in young children-with moderately severe asthma. Pediatr. Pulmonol. 24:397-405.
18. Smith, A.L., B.W. Ramsey, D.L. Hedges, et al. 1989. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. 7:265-271.
19. Konstan, M.W., S.M. Butler, D.V. Schidlow, et al. 1999. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr. Pulmonol. 28:248-254.
20. Clay, M.M., D. Pavia, S.P. Newman, et al. 1983. Assestment of jet nebulizers for lung aerosol therapy. Lancet 1:592-594.
21. Hallworth, G.N., and U.G. Andrews. 1977. Size analysis of suspension inhalation by inertial separation methods. J. Pharm. Pharmacol. 28:898-907.
22. Waters Chromatography Application Note. 2003. Albuterol HPLC Method.
23. Nilsson, G., A. Brunzell, and H. Hellberg. 1977. Estimation of particle size in medical aerosols with a cascade impactor. Acta Pharm. 14:95-104.
24. Berlinski, A., and J.C. Waldrep. 1997. Effect of aerosol delivery system and drug formulation on nebulized budesonide output. J. Aerosol Med. 10:307-318.
25. Rau, J.L. 2002. Design principles of liquid nebulization devices currently in use. Respir. Care 47:1257-1275.
26. O'Callaghan C, and P.W. Barry. 1997. The science of nebulized drug delivery. Thorax 52:531-544.
27. Stahlhofen, W., J. Geghart, and J. Heyder. 1980. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am. Ind. Hyg. Assoc. 41:385-398a.
28. 2 agonists and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51:977-980.
29. Usmani, O.S., M.F. Biddiscome, J.A. Nightingale, et al. 2003. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J. Appl. Physiol. 95:2006-2112.
30. Clark, A.R. 1995. The use of laser diffraction for the evaluation of aerosol cloudss generated by medical nebulizers. Int. J. Pharm. 115:69-78.
31. de Boer, A.H., D. Gjaltema, Hageedoorn, P., et al. 2002. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int. J. Pharm. 249:219-231.
32. Dolovich, M.B. 2002. Assessing nebulizer performance. Respir. Care 47:1290-1301.
33. Dennis, J.H. 1995. Drug nebulizer design and performance: breath enhanced vs. constant output jet nebulizer ultrasonic. J. Aerosol Med. 8:277-280.